Shots:

• The NMPA has approved an IND submission for P-II trial to evaluate the efficacy of enoblituzumab + pembrolizumab in patients with solid tumors, including NSCLC, UC & other cancers
• I-Mab has obtained exclusive rights to develop & commercialize enoblituzumab in Greater China from MacroGenics. In preclinical studies, enoblituzumab showed strong anti-tumor activity while preliminary clinical evidence from MacroGenics support increased efficacy for combination of enoblituzumab and pembrolizumab against cancers.
• MacroGenics is planning to conduct a P-II study of enoblituzumab + retifanlimab or tebotelimab for the treatment of recurrent or metastatic SCCHN

Ref: PR Newswire | Image: I-Mab